Cellular Senescence 48 min read January 27, 2026

Cellular Senescence: What Can Be Done About It?

Exploring therapeutic approaches to target senescent cells and the challenges in developing safe and effective senolytics.

Part 2: "Cellular Senescence: What Can Be Done About It?"

Brief overview/Summary

Cellular senescence is a natural process with both protective and harmful effects. Throughout life, senescence helps prevent tumor formation and mitigate tissue damage. However, as individuals age, senescent cells accumulate in tissues, potentially contributing to various age-related diseases. Recent research has uncovered the molecular mechanisms that support the survival of senescent cells and regulate their immune clearance. These findings provide a foundation for developing new therapeutic approaches to target senescent cells while highlighting the importance of understanding the limitations, efficacy, safety, and potential risks of current strategies for senescent cell elimination.

This article explores existing methods for targeting senescent cells and the challenges in advancing these strategies into safe and effective therapies. Successfully addressing these challenges could revolutionize treatments for age-related diseases and transform the way we approach health management during aging.

Introduction

The global population is aging rapidly, presenting both opportunities and significant challenges, particularly as advanced age increases susceptibility to chronic diseases. Aging is the leading risk factor for many of the world’s most prevalent conditions, including cardiovascular diseases, cancer, and neurodegenerative disorders. However, aging is not uniform—some individuals maintain better health and functionality than others at the same chronological age, experiencing longer periods of well-being. This underscores the importance of understanding the shared cellular and molecular pathways that drive age-related multimorbidity’s. Targeting these pathways may offer more effective treatments than addressing each disease in isolation. Recent discoveries have shed light on the biological mechanisms underlying aging, with one key factor being the accumulation of senescent cells in tissues.

Cellular senescence is a largely irreversible arrest of the cell cycle in normal, proliferating cells, triggered by various stressors such as replicative exhaustion, oncogene activation, DNA damage, and cell-cell fusion. This response, mediated by the DNA damage response pathway, serves as a protective mechanism to prevent the propagation of damaged cells. Cellular senescence plays crucial roles in tumor suppression, limiting tissue damage, and aiding wound healing. However, despite these protective effects, the persistent presence of senescent cells can have detrimental consequences.

Senescent cells secrete a complex mix of proinflammatory factors, which, while aiding their removal by the immune system, can contribute to chronic inflammation when these cells accumulate. Evidence from studies on animal models suggests that components of the immune system, such as NK cells, T cells, and macrophages, play a role in regulating senescent cell presence in tissues. However, the effectiveness of this immune-mediated clearance varies depending on the tissue and pathological conditions, and the mechanisms governing the balance of senescent cells remain incompletely understood.

In advanced age, senescent cells accumulate in tissues and promote a state of chronic, low-grade inflammation—termed "inflammaging"—through continuous secretion of proinflammatory cytokines. This phenomenon is closely associated with most age-related diseases. Senescent cells are particularly prevalent in areas affected by age-related pathologies, and mounting evidence from mouse models indicates that these cells play a causal role in conditions such as atherosclerosis, idiopathic pulmonary fibrosis, osteoarthritis, bone loss, and hepatic steatosis. Notably, genetic strategies to enhance the clearance of senescent cells expressing the p16 marker in mice have been shown to delay the onset of age-related tissue deterioration and extend median lifespan.

Therapeutic Strategies for Targeting Senescent Cells

Interest in targeting senescent cells therapeutically is rapidly growing, with several promising strategies under development. These approaches focus on either clearing senescent cells or mitigating their proinflammatory effects. A key area of research involves the discovery of pharmacological agents, known as "senolytics," which can selectively induce the death of senescent cells.

These efforts leverage the unique molecular characteristics of senescent cells, particularly their ability to accumulate with age and their distinct biological features compared to other cell types. One notable hallmark of senescent cells is their resistance to apoptosis. Unlike normal cells, senescent cells are shielded from both intrinsic and extrinsic proapoptotic signals, enabling them to persist and influence various biological processes even under stress.

By targeting these apoptotic pathways specifically in senescent cells, senolytic therapies can induce their selective elimination, effectively preventing the harmful effects associated with their accumulation. This pharmacological approach differs in several respects from genetic strategies but offers a compelling method to address the detrimental impact of senescent cells on aging and age-related diseases.

****

Three principal approaches could be implemented to block deleterious effects of senescent cells. (A) The leading options are strategies that induce apoptosis selectively in senescent cells with the use of senolytic drugs, which block pro-survival pathways. (B) The second type of strategy is to potentiate an immune response against senescent cells in a way that would lead to their clearance from tissues. (C) A third strategy proposes specific blockade of SASP components by targeting their upstream regulators and effectors. ADCC, antibody-dependent cell-mediated cytotoxicity; DDR, DNA damage response; GOS, galacto-oligosaccharides; ITAM, immunoreceptor tyrosine-based activation motif.

Blocking Survival Pathways

Several pro-survival pathways have been identified as potential targets for the directed elimination of senescent cells, including the BCL-2 protein family, the p53/p21 axis, PI3K/AKT, receptor tyrosine kinases, and the HIF-1α and HSP90 proteins. Among these, the BCL-2 protein family has garnered significant attention due to its role in regulating apoptosis and autophagy, making it a particularly attractive drug target. During senescence, antiapoptotic proteins such as BCL-2, BCL-W, and BCL-XL are upregulated in various cell types, and silencing these proteins triggers programmed cell death.

Pharmacological inhibitors of the BCL-2 family have been extensively studied in cancer therapy and have shown promise as senolytics. ABT-737, a BH3 mimetic, disrupts the interaction between antiapoptotic BCL-2 family members and proapoptotic proteins, allowing senescent cells to undergo apoptosis. In mouse models, ABT-737 effectively clears senescent cells induced by DNA damage or p14ARF activation, even promoting hair follicle stem cell proliferation and hair growth. A next-generation analog, ABT-263 (navitoclax), has demonstrated the ability to eliminate senescent muscle and hematopoietic stem cells in aged and irradiated mice, rejuvenating these populations. It also removes senescent foam cell macrophages from atherosclerotic plaques, halting disease progression.

Despite these benefits, general inhibitors of BCL-2, BCL-W, and BCL-XL, such as ABT-737 and ABT-263, cause hematological toxicities, including neutropenia and thrombocytopenia. These side effects highlight the need for more selective inhibitors. For example, BCL-XL-specific inhibitors like A1331852 and A1155463 may reduce toxicity in non-senescent cells while still inducing apoptosis in senescent cholangiocytes and fibroblasts, as demonstrated in a mouse model of biliary liver fibrosis. However, platelet survival depends on BCL-XL, so transient thrombocytopenia remains a concern, and these inhibitors may be less effective against senescent cells expressing higher levels of BCL-2 or BCL-W.

Localized administration of BCL-2 family inhibitors could mitigate systemic side effects. For instance, intra-articular injection of UBX0101, a BCL-2-targeting compound, successfully cleared senescent cells from articular cartilage and synovium, reducing osteoarthritis symptoms in aged mice. While targeting the BCL-2 family represents a validated approach for senescent cell clearance, its clinical utility may be limited by associated toxicities, underscoring the need for more precise and localized therapeutic strategies.

Senolytic Combinations

A potential strategy to mitigate the cytotoxic side effects of BCL-2 protein family inhibitors is to combine low doses of these inhibitors with compounds that target other senescence-associated pro-survival pathways. Notably, the first senolytic discovered was not a single compound but a combination of the pan-tyrosine kinase inhibitor dasatinib and the naturally occurring flavonoid quercetin. Together, these compounds were shown to selectively eliminate senescent primary preadipocytes and senescent human umbilical vein endothelial cells (HUVECs) in tissue culture and reduce senescent cell signatures across several pathological conditions. In animal models, dasatinib/quercetin reduced aortic calcification and osteogenic signaling in aged and hypercholesterolemic mice and improved lung function in mice with bleomycin-induced lung fibrosis. However, the combination failed to address the fibrotic components of these conditions, suggesting its greater utility as a preventative intervention in early disease stages. Supporting this, dasatinib/quercetin has been shown to prevent age-related bone loss and reduce hepatic steatosis, a precursor to nonalcoholic fatty liver disease.

Both dasatinib and quercetin have been tested in clinical settings, making this combination a promising candidate for senolytic therapy. However, several challenges may limit its broader application. For one, both compounds target numerous biological pathways, and the mechanisms underlying their senolytic effects are not fully understood. Furthermore, the combination’s effects likely arise from alterations in multiple pathways across various tissues and organs, raising concerns about potential adverse effects with long-term use. Nevertheless, short-term administration of the combination has proven sufficient to eliminate senescent cells and confer therapeutic benefits in preclinical studies. Since continuous presence of the compounds may not be necessary, the risk of off-target complications could be minimized.

Beyond quercetin, other natural compounds such as fisetin and piperlongumine have also demonstrated senolytic potential. These molecules are believed to target multiple molecular pathways to eliminate senescent cells. However, their unclear mechanisms of action and poor pharmacokinetic profiles make it unlikely that they will be developed into clinical therapies.

Targeting Senescence Specific Pathways

Recent studies have identified the p53/p21 axis as a promising target for developing novel senolytics. p53, a key tumor suppressor gene and the most frequently mutated in human cancers, is a central regulator of the senescence program. Stabilized in response to DNA damage, p53 accumulates and exerts transcriptional control over numerous processes, acting as a critical decision point between transient cell cycle arrest, senescence, and apoptosis. Disrupting the interaction between p53 and the transcription factor FOXO4 induces the release of p53 from the nucleus, triggering cell-intrinsic apoptosis. Administration of a modified peptide that interferes with the p53-FOXO4 interaction reversed liver chemotoxicity from doxorubicin in mice, while improving fitness, hair density, and kidney function in progeroid and naturally aged mice. Beyond the p53-FOXO4 interaction, p21 (CDKN1A), a primary transcriptional target of p53, also plays a vital role in senescent cell survival and retention. Following DNA damage, p21 prevents NF-κB–mediated JNK activation, caspase-3 cleavage, and subsequent apoptosis. In mouse models, p21 knockout reduced senescent cells in fibrotic livers and alleviated fibrosis. While indirect modulation of the p53/p21 axis, such as controlling ROS levels, is possible, no drugs currently induce apoptosis in senescent cells by directly inhibiting p53 or p21. Further research is essential to realize the therapeutic potential of this pathway. The FOXO4 peptide represents a promising starting point for senolytic development, and peptide-based or mimetic approaches could form the basis for future treatments.

The discovery of molecular pathways supporting senescent cell viability has been crucial for senolytic development. In addition to targeting specific pathways, high-throughput methods have identified novel targets, including the HSP90 protein family. HSP90, a group of molecular chaperones, promotes cell survival by stabilizing signaling proteins like AKT and ERK, which are upregulated during senescence. Disrupting the HSP90-AKT interaction inhibits the PI3K/AKT pathway, selectively killing senescent cells from various origins. In vivo, treatment with the HSP90 inhibitor 17-DMAG in progeroid mice reduced senescence markers and extended health span. These findings suggest HSP90 inhibitors could play a critical role in combinatorial senolytic therapies, paving the way for more effective interventions.

Directed Elimination of Senescence Cells

Targeting senescence-specific pathways is a promising strategy for developing senolytics, but other unique features of senescent cells can also be exploited for their elimination. One such feature is the increased activity of senescence-associated β-galactosidase (SA β-gal). Leveraging this, researchers have designed a delivery system using mesoporous silica nanoparticles coated with galacto-oligosaccharides. These nanoparticles remain inactive in non-senescent cells but are activated in senescent cells, where the coating is digested, allowing the nanoparticle contents to be released. For instance, cytotoxic drugs encapsulated in these coated nanoparticles could be selectively released into the cytoplasm of senescent cells, inducing apoptosis.

However, SA β-gal activity is not an exclusive marker of senescent cells, as certain other cell types, such as macrophages, can exhibit elevated β-galactosidase activity under specific conditions). To enhance selectivity, these nanoparticles could be tethered to antibodies targeting known surface markers unique to senescent cells. While senolytic strategies based on SA β-gal activity are conceptually promising, they have yet to be tested in vivo. Further studies are required to evaluate their efficacy and safety in treating senescence-associated conditions.

Immune Mediated Interventions

Beyond directly eliminating senescent cells based on their intrinsic properties, therapeutic interventions can leverage the immune system. Senescent cells are naturally immunogenic and subject to immune surveillance mechanisms. In a hepatocellular carcinoma model, p53 restoration induces senescence and triggers an innate immune response involving leukocytes, neutrophils, macrophages, and NK cells. Similarly, in a liver fibrosis model, senescent hepatic stellate cells promote their elimination by NK cells. Senescent cells often upregulate NKG2D, an immune recognition molecule absent on normal cells, making it a promising target for immunotherapy approaches. However, senescence surveillance mechanisms vary by context. For instance, senescence induced by NRASG12V expression in hepatocytes results in a mixed immune response, with CD4+ T cells and monocytes/macrophages cooperating to clear senescent cells. The accumulation of senescent cells in aged tissues may result partly from immune decline with age. Enhancing immune function could support the clearance of these cells. Supporting this, the immune stimulator polyI:C facilitates NK cell–mediated clearance of senescent cells in fibrotic livers. However, such strong immune stimulators may overwhelm the already chronically activated aging immune system, necessitating more precise modulators.

Adopting immunotherapy strategies from cancer treatment could aid these efforts. For example, blocking the immune checkpoint programmed death 1 (PD-1), a powerful cancer therapy, also alleviates symptoms in a murine model of Alzheimer’s disease. Additionally, tools like chimeric antigen receptor (CAR) T cells could redirect immune responses to target senescent cells. However, a major challenge in immune-based approaches is the limited availability of highly specific senescence markers. Recent studies have identified promising candidates. Senescent fibroblasts were found to express an oxidized form of membrane-bound vimentin on their surface, and mass spectrometry identified dipeptidyl peptidase 4 (DPP4) as a cell surface marker for senescent fibroblasts. DPP4’s selective expression allows NK cells to target senescent cells via antibody-dependent cell-mediated cytotoxicity (ADCC). However, senescent cells are partially protected from NK cell–mediated killing due to upregulation of decoy receptor 2 (DcR2), which inhibits death receptor activation by TNF-related apoptosis-inducing ligand (TRAIL), confining cytotoxicity to perforin- and granzyme-mediated pathways. Strategies to block DcR2 could enhance senescent cell vulnerability to natural immune clearance and immunotherapy.

Strategies Aimed to Limit Detrimental Roles of Senescent Cells

While eliminating senescent cells is a promising strategy, it may not be suitable for all conditions where senescent cells are present. In such cases, targeting the harmful components of senescence could serve as an alternative approach. Senescent cells exhibit a consistent proinflammatory secretory profile, known as the senescence-associated secretory phenotype (SASP), which is conserved across different senescent states and cell types. The SASP consists of inflammatory chemokines, cytokines, growth factors, and matrix-remodeling proteases. While the SASP plays a role in tumor suppression by enforcing cell cycle arrest in damaged cells and recruiting immune cells for clearance, it is also implicated in disrupting tissue homeostasis and driving age-related pathologies. Several signaling pathways, including the NF-κB and C/EBPβ pathways, regulate the SASP and can be modulated by various FDA-approved drugs. For example, IL-1α signaling upstream of NF-κB can be inhibited with neutralizing antibodies against IL-1α or its receptor, reducing NF-κB activity. mTOR inhibitors like rapamycin can suppress SASP by lowering IL-1α expression, mitigating senescent fibroblasts' ability to promote tumor growth in mice. Metformin, widely used for type 2 diabetes, blocks NF-κB nuclear translocation, limiting inflammation, alleviating age-related pathologies, and extending lifespan in mice. Ongoing studies explore its anti-aging potential in non-diabetic populations. C/EBPβ activity, induced by JAK/STAT signaling, can be reduced with JAK1/2 inhibitors like ruxolitinib, improving systemic inflammation and fitness in aged mice. These findings suggest that existing drugs may dampen the SASP's effects in vivo, potentially mitigating the negative impact of senescent cells.

Restricting inflammation to limit the harmful effects of senescent cells shows promise, but prolonged use of potent anti-inflammatory drugs may cause side effects. This limitation could hinder long-term treatment necessary to retain senescence's beneficial effects. Recent studies on epigenetic regulators such as MLL1, BRD4, and HMGB2 may provide a solution. These proteins reshape the epigenetic landscape of senescent cells, influencing SASP expression. Knocking down these chromatin modifiers sustainably suppresses inflammation without affecting cell cycle arrest. Small-molecule modulators, including bromodomain and extra-terminal motif (BET) inhibitors, could be explored further for their potential in this area. Targeting specific SASP components may also provide a safer approach. Well-defined SASP cytokines like IL-6 and IL-8 or matrix-remodeling proteases like ADAM17 represent viable targets. Neutralizing antibodies, developed from commercially available monoclonal antibodies, could block these molecules effectively. For instance, IL-6 or its receptor can be targeted with approved drugs like siltuximab or tocilizumab, which block the cytokine or its receptor, respectively. However, these agents were not initially designed for senescence-related applications, and further research is needed to assess their effects on SASP and aging before therapeutic use as senescence modifiers.

Moving Toward Clinical Trials

Successful translation of strategies aimed at targeting senescent cells into the clinic could have a vast impact on the treatment of a variety of diseases at old age and potentially revolutionize our view of aging. Several technologies aiming at senescent cells are now taking their first steps in the challenging, time-consuming, and expensive journey of drug development. In order to maximize their chances of becoming common treatments, critical issues of efficacy, safety, and tolerability should be considered during the early stages of development.

Sources:

Product available for research use only:

Posted in: FOXO4-DRI Cellular Senesence

Be the first to know

Receive all the latest information on events, sales, & offers.

Terms and Conditions of Purchase

Your Use of Our Web Site

Unless specified otherwise, your use of this Web Site is governed by this Terms and Conditions of Use Agreement and the Privacy Policy, which is incorporated herein by this reference. In using this Web Site, you are prohibited from modifying, distributing, transmitting, reproducing, publishing, licensing, transferring, or selling any information, products or services obtained or viewed on this Web Site. However, you may display, download, or print hard copies of any material contained on this Web Site for your own personal, non-commercial use as long as you do not modify the content or delete any copyright, trademark, or other proprietary notice. Any other use of the information contained on this Web Site is prohibited without our express written consent.

All ACH/e-Check payments will be made payable to:

P-Sciences, Inc.

Each time I (the customer) places an ACH/e-Check order by clicking the "Place Order" button, I am authorizing to initiate a single ACH/electronic debit to my account in the amount of my order from the bank account information provided on the date of my order. I agree that ACH transactions I authorize comply with all applicable law. Payments made after 11 P.M. pacific time will be applied as of the next business day. To complete the payment process, click the “Place Order” button. Once payment is authorized, there cannot be any changes or corrections. It is recommended that you print a copy of this authorization and maintain it for your records.

Use of Information

This Web site provides information that, while useful, must not be used as a substitute for the advice of your own advisors. Information available from this Web Site is not intended to be used to diagnose any medical condition or disease. Products on this website are sold for laboratory research purposes only.

reserves the right to correct any inaccuracies or typographical errors in the information posted on this Web Site, and shall have no liability for such errors. Information may be changed or updated without notice and prices and availability of goods and services are subject to change without notice.

DISCLAIMER:

YOU MUST BE OVER 21 YEARS OLD TO USE THIS WEBSITE.

The products we offer are intended for IN-VITRO LABORATORY RESEARCH USE ONLY-- NOT FOR HUMAN USE.

In purchasing any of these items, the customer acknowledges that there are risks involved with consumption or distribution of these products.

These chemicals are NOT intended to use as food additives, drugs, household chemicals or other inappropriate applications.

The listing of a material on this site does not constitute a license to its use in infringement of any patent.

All of the products will be handled only by qualified and properly trained RESEARCH or LABORATORY professionals only.

Due to the nature of these products ALL SALES ARE FINAL. WE CANNOT ACCEPT RETURNS. ALL SALES ARE FINAL.

All customers represent and warrant that through their own review and study that they are fully aware and knowledgeable about the following:

Use of the products and more specifically In-vitro Research use of the products.

Your specific countries Government regulations regarding the use of and exposure to all products.

The health and safety hazards associated with the handling of the products they purchase.

The necessity of adequately warning of the health and safety hazards associated with any products.

reserves the right to limit and/or deny sales of products to any unqualified individuals. All customers MUST be at least 21 years of age to purchase our products. IN NO CIRCUMSTANCE SHALL BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER PURCHASER'S CLAIM IN CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE. IN DIRECT CONSIDERATION OF APPROVING THE SALE OF ANY PRODUCT TO THE PURCHASER, THE PURCHASER AGREES TO INDEMNIFY AND HOLD US HARMLESS FROM ALL CLAIMS, EXPENSES, LOSSES AND LIABILITY OF ANY TYPE ARISING OUT OF THE PURCHASER'S HANDLING, POSSESSION, AND/OR USE OF THE PRODUCT, WHETHER USED ALONE OR IN COMBINATION WITH ANY SUBSTANCE. ANY SALE WOULD BE DENIED OTHERWISE.

PRODUCT USE:

products are intended for laboratory IN-VITRO RESEARCH PURPOSES ONLY-- NOT FOR HUMAN USE and are not to be used for any other purposes, including but not limited to food and/or drugs, medical devices, vitro diagnostic purpose, or for commercial purposes. The purchaser agrees that the products have not been sterilized or tested by for safety and efficacy in food, drug, medical device, cosmetic, commercial or any other use. The purchaser expressly represents and warrants to that the purchaser will properly test, use, manufacture and market any products purchased from and/or materials produced with products purchased from in accordance with the practices of a reliable person who is experienced in the field and in strict compliance with all applicable laws and regulations, now and hereinafter enacted. The purchaser further warrants that any material produced with any product shall not be adulterated or misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act and shall not be materials which may not, under Sections 404, 505, or 512 of the Act, be introduced into interstate commerce.

The purchaser realizes that, since products are, unless otherwise stated, intended solely for in-vitro research purposes, they may not be on the Toxic Substances Control Act (TSCA) inventory listing. The purchaser assumes responsibility to assure that the products purchased from are approved for use under TSCA, if applicable.

Purchaser has the responsibility to verify the hazards and to conduct any further research necessary to learn the hazards involved in using products purchased from Purchaser agrees to comply with instructions, if any, furnished by relating to the use of the products and not misuse the products in any manner. No products purchased from shall, unless otherwise stated, be considered to be foods, drugs, or medical devices.

ALL products and services offered are for IN-VITRO RESEARCH purposes ONLY and are NOT TO BE INGESTED or CONSUMED IN ANY MANNER.

ALL PRODUCTS SOLD BY THE ARE NOT TO BE USED FOR PERSONAL USE OR FOR THE TREATMENT OF ANY MEDICAL CONDITION OR DISEASE.

Under NO circumstances shall/ should ANY of these materials be used for recreational purposes nor human consumption of any kind.

is NOT liable for ANY damages that may be caused by negligence, abuse, or ANY other unforeseen matter.

All items sold are legal for sale for IN-VITRO RESEARCH PURPOSES SPECIFICALLY within the USA.

Trade-Marks and Other Intellectual Property Rights

"" is a registered trademark of

All text, graphics, user interfaces, visual interfaces, photographs, trademarks, logos, sounds, music, artwork and computer code (collectively, "Content"), including but not limited to the design, structure, selection, coordination, expression, "look and feel" and arrangement of such Content, contained on this Web Site is owned, controlled or licensed by or to and is protected by copyright, patent and trademark laws, and various other intellectual property rights and unfair competition laws.

Except as expressly provided in this Terms and Conditions of Use Agreement, no part of this Web Site and no Content may be copied, reproduced, republished, uploaded, posted, publicly displayed, encoded, translated, transmitted or distributed in any way (including "mirroring") to any other computer, server, web site or other medium for publication or distribution or for any commercial enterprise, without express prior written consent.

Indemnity

You hereby agree to indemnify and hold and our subsidiaries, affiliates, officers, directors, agents, co-branders, partners, and employees harmless from any claim or demand, including reasonable attorney's fees, made by any third party due to or arising out of your use of the content on this Web Site, or any content you submit, post, or transmit through this Web Site, your use of this Web Site, your connection to this Web site, your violation of this Terms and Conditions of Use Agreement, or your violation of any rights of another.

Links/Software

Links from or to websites outside this Web Site are meant for convenience only. does not review, endorse, approve or control, and is not responsible for any sites linked from or to this Web Site, the content of those sites, the third parties named therein, or their products or services. Linking to any other site is at your sole risk and will not be responsible or liable for any damages in connection with linking. disclaims all warranties, express and implied as to the accuracy, validity and legality of any materials or information found on those sites. Links to downloadable software sites are for convenience only and is not responsible or liable for any difficulties or consequences associated with downloading the software. Use of any downloaded software is governed by the terms of the license agreement, if any, which accompanies or is provided with the software.

Availability of Our Web Site

This Web Site is generally available to users Twenty-four (24) hours per day, Seven (7) days per week, Three Hundred Sixty-five (365) days per year. However, retains the right to make our Web Site unavailable at any time, for any reason, and for any length of time. By using this Web Site you agree that will not be liable for any damage arising out of or related to any such interruption, suspension, or termination of this Web Site and/or the services or products contained therein. Upon acceptance of these terms and conditions of use authorizes you to view the Content on the Web Site solely for your personal use. The material on the Web Site is intended solely for individuals enquiring about products or services. If you are not accessing the Web Site for such purposes, you may not use the Web Site. For certainty, use by non-individuals or the agents, attorneys or representatives of non-individuals is prohibited.

**Information You Provide

Our collection and/or use of any information you provide while using or visiting this Web Site is governed by the Privacy Policy and this Terms and Conditions of Use Agreement. By using this Web Site you grant us the rights contained therein. In using this Web Site you may not upload, distribute, or otherwise publish on this Web Site any information which may be viewed as obscene, defamatory, libelous, threatening, abusive, illegal, an invasion of privacy rights, or otherwise objectionable, or may constitute or encourage a violation of any law.

Except for that individually-identifiable information collected from you in accordance with our Privacy Policy, all comments, remarks, suggestions, ideas or other information communicated will become the exclusive property of and you grant to a royalty-free, perpetual, irrevocable, world-wide, non-exclusive license to use or reproduce the same. is free to copy, disclose, distribute or analyze any such information for any and all purposes and are in no way obligated to compensate you for any such information.

Disclaimer of Warranties

PROVIDES CONTENT ON THIS WEB SITE AS A SERVICE TO YOU, OUR CUSTOMER. THIS WEB SITE CANNOT AND DOES NOT, CONTAIN INFORMATION ABOUT ALL APPLICATIONS FOR PRODUCTS SOLD. IT MAY NOT CONTAIN ALL INFORMATION THAT IS APPLICABLE TO YOUR PERSONAL CIRCUMSTANCES OR YOUR USE OF PRODUCTS SOLD. THE CONTENT OF THIS WEB SITE, THE WEB SITE SERVER THAT MAKES IT AVAILABLE, AND THE SERVICES AND PRODUCTS PROVIDES ON THIS WEB SITE, ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS WITHOUT WARRANTY OF ANY KIND, WHETHER EXPRESS, IMPLIED OR STATUTORY. EXPRESSLY DISCLAIMS LIABILITY FOR TECHNICAL FAILURES (INCLUDING HARDWARE OR SOFTWARE FAILURES), INCOMPLETE, SCRAMBLED OR DELAYED COMPUTER TRANSMISSIONS, AND/OR TECHNICAL INACCURACIES, AS WELL AS UNAUTHORIZED ACCESS OF USER TRANSMISSIONS BY THIRD PARTIES. FURTHER, DOES NOT REPRESENT OR WARRANT THAT NO VIRUSES OR OTHER CONTAMINATING OR DESTRUCTIVE PROPERTIES WILL BE TRANSMITTED, OR THAT NO DAMAGE WILL OCCUR TO YOUR COMPUTER SYSTEM. YOU HAVE SOLE RESPONSIBILITY FOR ADEQUATE PROTECTION AND BACKUP OF DATA AND/OR EQUIPMENT AND TO TAKE ALL PRECAUTIONS TO SCAN FOR COMPUTER VIRUSES OR OTHER DESTRUCTIVE PROPERTIES. BY YOUR USE OF THIS WEB SITE, YOU ACKNOWLEDGE THAT SUCH USE IS AT YOUR SOLE RISK, INCLUDING RESPONSIBILITY FOR ALL COSTS ASSOCIATED WITH ALL NECESSARY SERVICING OR REPAIRS OF ANY EQUIPMENT YOU USE IN CONNECTION WITH THIS WEB SITE.

TO THE FULL EXTENT NOT PRECLUDED BY APPLICABLE LAW THEIR MEDICAL ADVISORS, SUPPLIERS, CONSULTANTS, DIRECTORS AND EMPLOYEES DISCLAIM AND EXCLUDE ALL WARRANTIES WITH RESPECT TO ALL CONTENT, EXPRESS, IMPLIED OR STATUTORY. THIS DISCLAIMER INCLUDES, BUT IS NOT LIMITED TO, ANY AND ALL WARRANTIES OR MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT. DOES NOT WARRANT THE CONTENT TO BE ACCURATE, COMPLETE OR CURRENT. DOES NOT WARRANT THAT THIS WEB SITE WILL OPERATE WITHOUT ERROR, THAT DEFECTS WILL BE CORRECTED OR THAT THIS WEB SITE OR THE WEB SITE SERVER MAKING IT AVAILABLE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. PRICE AND AVAILABILITY CONTENT, AS WELL AS OTHER CONTENT CONTAINED IN THIS WEB SITE OR ACCESSIBLE THEREFROM, IS SUBJECT TO CHANGE WITHOUT NOTICE.

YOU ACKNOWLEDGE AND AGREE THAT DOES NOT ENDORSE THE CONTENT OF ANY SITE ACCESSED VIA LINKS OR OTHER MEANS FROM THIS WEB SITE AND IT IS NOT RESPONSIBLE OR LIABLE FOR SUCH CONTENT EVEN THOUGH IT MAY BE UNLAWFUL, HARASSING, LIBELOUS, PRIVACY INVADING, ABUSIVE, THREATENING, HARMFUL, OBSCENE, OR OTHERWISE OBJECTIONABLE, OR THAT IT INFRINGES OR MAY INFRINGE THE INTELLECTUAL PROPERTY OR OTHER RIGHTS OF ANOTHER PERSON.

THIS WEB SITE INCLUDES CONTENT PROVIDED BY THIRD PARTIES AND YOU, OUR CUSTOMER. IS A DISTRIBUTOR OF SUCH CONTENT AND NOT ITS PUBLISHER. EDITORIAL CONTROL OF SUCH CONTENT IS THE SAME AS THAT OF A PUBLIC LIBRARY OR NEWSSTAND. THIRD PARTY SUPPLIERS MAY EXPRESS CERTAIN OPINIONS OR PROVIDE CERTAIN INFORMATION AND OFFERS. MAKES NO WARRANTIES AS TO THE COMPLETENESS, ACCURACY, TIMELINESS, OR RELIABILITY OF INFORMATION OR OFFERS SUPPLIED BY THIRD PARTIES. DOES NOT GUARANTEE OR WARRANT THE PERFORMANCE OF ANY THIRD PARTY, INCLUDING ANY SUCH THIRD PARTY’S CONFORMANCE TO ANY LAW, RULE, REGULATION OR POLICY.

DOES NOT WARRANT THAT INFORMATION, SERVICES, AND PRODUCTS CONTAINED IN THIS WEB SITE WILL SATISFY YOUR REQUIREMENTS OR THAT THEY ARE ERROR OR DEFECT-FREE. BEFORE USING ANY PRODUCT YOU SHOULD CONFIRM ANY INFORMATION OF IMPORTANCE TO YOU ON THE PRODUCT PACKAGING. YOU ASSUME RESPONSIBILITY FOR THE ACCURACY, APPROPRIATENESS AND LEGALITY OF ANY INFORMATION YOU SUPPLY

AS PARTIAL CONSIDERATION FOR YOUR ACCESS TO THIS WEB SITE AND USE OF ITS CONTENT, YOU AGREE THAT IS NOT LIABLE TO YOU IN ANY MANNER WHATSOEVER FOR DECISIONS YOU MAY MAKE OR YOUR ACTIONS OR NON-ACTIONS IN RELIANCE UPON THE CONTENT. YOU ALSO AGREE THAT THE AGGREGATE LIABILITY OF ARISING FROM OR RELATED TO YOUR USE AND ACCESS REGARDLESS OF THE FORM OF ACTION OR CLAIM (FOR EXAMPLE, CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY, PROFESSIONAL MALPRACTICE, FRAUD, OR OTHER BASES FOR CLAIMS), IS LIMITED TO THE PURCHASE PRICE OF ANY ITEMS YOU PURCHASED FROM IN THE APPLICABLE TRANSACTION. SHALL NOT IN ANY CASE BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES EVEN IF HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS IS A COMPREHENSIVE LIMITATION OF LIABILITY THAT APPLIES TO ALL LOSES AND DAMAGES OF ANY KIND. IF YOU ARE DISSATISFIED WITH THIS WEB SITE OR ITS CONTENT (INCLUDING TERMS OF USE), YOUR SOLE EXCLUSIVE REMEDY IS TO DISCONTINUE USING THIS WEB SITE. BECAUSE SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES, SUCH LIMITATION MAY NOT BE APPLICABLE TO YOU.

Your Agreement to Abide by All Applicable Laws

By using this Web Site you agree to comply with any and all local, state, or federal laws, statutes, and regulations that relate in any manner to the use of this Web Site and the associated services or products contained thereon.

Relationship between and Users.

and users of our Site are independent contractors, and no agency, partnership, employment or other relationship is created or is intended to be created by the use of our Web Site.

Governing Law and Jurisdiction

This Web Site (excluding linked sites, if any) is administered and controlled by and its affiliates, subsidiaries, officers, directors, employees or agents from its offices in the accordance with the laws of Nevis. You agree that this Terms and Conditions of Use Agreement and this Web Site will be governed by and construed in accordance Nevis law without giving effect to any principles of conflicts of laws. You access this Web Site and/or associated services of at your own risk, and remain responsible for complying with the laws of the jurisdiction within which you are located.

Prices; Payment Terms; Interest

The prices for the products and services on this Web Site are quoted, for convenience, in United States dollars and shall be as set forth in this Web Site as at the time of acceptance of an order by Prices for Products shall be subject to change without any further notice. Credit terms are within sole discretion, and unless otherwise specified in invoice, payment must be received by prior to acceptance of an order.

Consequences

reserves the right to suspend or terminate your account if you violate the Terms of Use Agreement. If your violation causes harm to others, you agree to indemnify and hold harmless from and against any and all loss, damage, or expense. If any dispute arises between us regarding this Agreement or your use of this Web Site, it shall be resolved through good faith negotiations between the parties.

Entire Agreement

These Terms and Conditions and any terms incorporated or referred to herein constitute the entire agreement between and you relating to your use of this Web Site and the subject matter hereof, and supersede any prior understandings or agreements (whether electronic, oral or written) regarding the subject matter, and may not be amended or modified except in writing, or by making such amendments or modifications in accordance with this Terms and Conditions of Use Agreement.

Severability

If any part of this Terms and Conditions of Use Agreement is deemed or determined to be unenforceable, then such part shall be eliminated or limited to the minimum extent necessary. The remainder of this Terms and Conditions of Use Agreement, including any revised portion, shall remain and be in full force and effect. This Terms and Conditions of Use Agreement are the entire agreement between us governing your use of this Web Site.

Headings

The headings contained in this Terms and Conditions of Use Agreement and the Privacy Policy are for reference only.

Force Majeure

shall not be liable for any delay or failure in performance caused by circumstances beyond its reasonable control, including, without limitation, delays due to backorders of requested products, mail delays, customs delays or lost shipments. shall not be responsible to notify the Customer in the event of such delays. The Customer shall be solely responsible to make other arrangements to purchase alternative products and any costs incurred in connection with such purchases.

Thank you again for visiting the Web Site.

Complete Agreement

Except as expressly provided in a particular "legal notice" on this Site, these Terms and Conditions constitute the entire agreement between you and this Site with respect to the use of this Site, and Content. By clicking “I agree” when placing your order, you agree with ALL OF OUR TERMS and CONDITIONS as stated above as well as our Shipping and refunds Policy.

Thank you for your cooperation.

Terms and Conditions of Purchase

Your Use of Our Web Site

Use of Information

DISCLAIMER:

Shipping address will be selected within Apple Pay. Any address entered in checkout will not be used.